Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINTRAVENOUSGeneric

CABAZITAXEL

CABAZITAXEL

Standard Dose
45MG/4.5ML (10MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary

Approval overview CABAZITAXEL is listed in Drugs@FDA under application 208715 (NDA).

Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CABAZITAXEL Form and strength SOLUTION;INTRAVENOUS - 45MG/4.5ML (10MG/ML) Sponsor SANDOZ Submission history Latest submission status date: 2023-10-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview CABAZITAXEL is listed in Drugs@FDA under application 208715 (NDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient CABAZITAXEL Form and strength SOLUTION;INTRAVENOUS - 45MG/4.5ML (10MG/ML) Sponsor SANDOZ Submission history Latest submission status date: 2023-10-27 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: None (Tentative Approval)
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.